Literature DB >> 17255747

Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome.

Diego Cecchini1, Juan Ambrosioni, Clarisa Brezzo, Marcelo Corti, Ana Rybko, Marcela Perez, Susana Poggi, Marta Ambroggi.   

Abstract

The objective of this study was to identify prognostic factors of death in patients with tuberculous meningitis (TM) and show the impact of infection by multidrug-resistant strains on the outcome of this disease. We retrospectively analysed clinical charts of HIV-infected patients with culture-confirmed TM attending our institution during 1996-2004. The following variables were associated with death during hospitalization: neurological signs at admission, a CD4 T-cell count less than 50 cells/microl and infection by multidrug-resistant strains.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17255747     DOI： 10.1097/QAD.0b013e328012b84d

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  15 in total

1.  Central Nervous System Tuberculosis: Challenges and Advances in Diagnosis and Treatment.

Authors:  Jerome H Chin; Farrah J Mateen
Journal:  Curr Infect Dis Rep       Date:  2013-10-12       Impact factor: 3.725

2.  Tuberculous meningitis: Diagnostic and therapeutic challenges.

Authors:  Jerome H Chin
Journal:  Neurol Clin Pract       Date:  2014-06

Review 3.  Tuberculosis of the central nervous system in immunocompromised patients: HIV infection and solid organ transplant recipients.

Authors:  Christina A Nelson; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2011-09-29       Impact factor: 9.079

4.  Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting.

Authors:  Suzaan Marais; Dominique J Pepper; Charlotte Schutz; Robert J Wilkinson; Graeme Meintjes
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

5.  Absence of cerebrospinal fluid pleocytosis in tuberculous meningitis is a common occurrence in HIV co-infection and a predictor of poor outcomes.

Authors:  Fiona V Cresswell; Ananta S Bangdiwala; David B Meya; Nathan C Bahr; Jose E Vidal; M Estée Török; Le Thi Phuong Thao; Guy E Thwaites; David R Boulware
Journal:  Int J Infect Dis       Date:  2018-01-31       Impact factor: 3.623

Review 6.  Tuberculous meningitis in HIV-infected individuals.

Authors:  Christopher Vinnard; Rob Roy Macgregor
Journal:  Curr HIV/AIDS Rep       Date:  2009-08       Impact factor: 5.071

7.  Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.

Authors:  S Dian; V Yunivita; A R Ganiem; T Pramaesya; L Chaidir; K Wahyudi; T H Achmad; A Colbers; L Te Brake; R van Crevel; R Ruslami; R Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 8.  Tuberculous meningitis in patients infected with human immunodeficiency virus.

Authors:  Ravindra Kumar Garg; Manish Kumar Sinha
Journal:  J Neurol       Date:  2010-09-17       Impact factor: 6.682

9.  Tuberculous meningitis: diagnosis and treatment overview.

Authors:  Grace E Marx; Edward D Chan
Journal:  Tuberc Res Treat       Date:  2011-12-21

10.  Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients.

Authors:  Gerardo Alvarez-Uria; Raghavakalyan Pakam; Manoranjan Midde; Pradeep Sukumar Yalla; Praveen Kumar Naik
Journal:  Interdiscip Perspect Infect Dis       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.